- Home
- MASK vs SPRO Comparison
MASK vs SPRO Comparison
Compare MASK & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASK
- SPRO
- Stock Information
- Founded
- MASK 2017
- SPRO 2013
- Country
- MASK China
- SPRO United States
- Employees
- MASK N/A
- SPRO N/A
- Industry
- MASK
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- MASK
- SPRO Health Care
- Exchange
- MASK NYSE
- SPRO Nasdaq
- Market Cap
- MASK 35.5M
- SPRO 33.0M
- IPO Year
- MASK 2025
- SPRO 2017
- Fundamental
- Price
- MASK $3.32
- SPRO $3.02
- Analyst Decision
- MASK
- SPRO Buy
- Analyst Count
- MASK 0
- SPRO 4
- Target Price
- MASK N/A
- SPRO $5.00
- AVG Volume (30 Days)
- MASK 58.4K
- SPRO 12.5M
- Earning Date
- MASK 01-01-0001
- SPRO 08-04-2025
- Dividend Yield
- MASK N/A
- SPRO N/A
- EPS Growth
- MASK 12.16
- SPRO N/A
- EPS
- MASK 0.19
- SPRO N/A
- Revenue
- MASK $4,718,055.00
- SPRO $44,584,000.00
- Revenue This Year
- MASK N/A
- SPRO N/A
- Revenue Next Year
- MASK N/A
- SPRO N/A
- P/E Ratio
- MASK $17.33
- SPRO N/A
- Revenue Growth
- MASK 7.89
- SPRO N/A
- 52 Week Low
- MASK $2.50
- SPRO $0.51
- 52 Week High
- MASK $4.19
- SPRO $3.06
- Technical
- Relative Strength Index (RSI)
- MASK N/A
- SPRO 79.94
- Support Level
- MASK N/A
- SPRO $2.81
- Resistance Level
- MASK N/A
- SPRO $3.06
- Average True Range (ATR)
- MASK 0.00
- SPRO 0.24
- MACD
- MASK 0.00
- SPRO -0.00
- Stochastic Oscillator
- MASK 0.00
- SPRO 93.75
About MASK 3 E NETWORK TECHNOLOGY GROUP LTD
3 E Network Technology Group Ltd is a business-to-business (B2B) information technology (IT) business solutions provider. It focuses on integrated software and hardware solutions in the property management and exhibition services spaces and expanded software solutions offering to a variety of industries and sectors, including food establishments, real estate, exhibition & conferencing, and clean energy utilities. The business includes two main portfolios, namely the software development portfolio and exhibition and conference portfolio. Maximum revenue is generated from the software development portfolio.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.